For research use only. Not for therapeutic Use.
Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research[1][2].
Pritumumab is effective in preventing tumor growth in nude mice but not in SCID mice[1].
Pritumumab can limit the growth of xenograft glioma tumors in vivo only in the presence of intact cell-mediated immunity[1].
| Catalog Number | I041544 |
| CAS Number | 499212-74-7 |
| Purity | ≥95% |
| Reference | [1]. Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017. [2]. Hugwil AV. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. Med Hypotheses. 2013 Sep;81(3):489-95. |
